Impact of CYP2D62A, CYP2D64 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.

Sherouk M OkdaNoha A El-BassiounyAhmed Mahmoud El AmrawyAhmad SalahuddinSohila M ElonsyAmira Bisher Kassem

Published in: British journal of clinical pharmacology (2024)

There is an association between CYP3A5*3, CYP2D6*4, CYP2D6*2A variants and bisoprolol peak concentration, which may serve as a guide in the future in choosing the optimum dose of bisoprolol in ACS patients.

Keyphrases

acute coronary syndrome
end stage renal disease
ejection fraction
chronic kidney disease
dna methylation
patient reported outcomes
coronary artery disease
antiplatelet therapy